Nanobiotix S.A

Nanobiotix reported €42.1 million in cash and cash equivalents as of March 31, 2026, which it expects will fund operations into 2029. The company completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including pre-funded warrants to accelerate development of its other platforms. New data from Part 1 of the Johnson & Johnson-sponsored Phase 2 CONVERGE study evaluating JNJ-1900 for Stage 3 inoperable non-small cell lung cancer were presented at the 2026 annual European Society for Radiotherapy and Oncology. The FDA accepted a protocol amendment to the ongoing pivotal J&J-sponsored NANORAY-312 study, eliminating a previously planned interim analysis and modifying the final analysis to include fewer events and be conducted sooner.